Sexo, drogas e (in)satisfação pessoal

Agradecendo a colegas da área de saúde da UFPE pela indicação, reproduzo aí abaixo paper de Helen Conaglen e John Canaglen sobre a relação entre a temática das drogas (aí incluídos os fármacos) e a questão da sexualidade. Como variável interveniente, em nossas pesquisas sobre as drogas, tem sido possível - seja do ponto de vista empírico, seja no tocante às ilações da literatura especializada - verificar um desvio padrão consistente, a depender da amostragem, no que se refere à correlação estatística entre drogas e sexo. Daí emergem também as inferências, convalidadas em estudos realizados em outros países, a respeito do 'desperdício da sexualidade', da 'sexualidade instantânea', da 'sexualidade dissociada de prazer físico-emocional', etc. São fenômenos que envolvem tanto o sexo masculino como o feminino. As razões para tanto são diversas. A seguir, a reprodução do paper.

Helen M Conaglen

Clinical psychologist and Senior research fellow, University of Auckland

John V Conaglen

Faculty of Medical and Health Sciences, University of Auckland

 (Publicado in: Australian Prescriber, v. 36, nº 02, 2013) 

Introduction

Several classes of prescription drugs contribute to sexual dysfunction in men and women (Table 1).1-3 Patients who develop drug-induced sexual dysfunction are more likely to be non-adherent. This has been found with antihypertensives4 and antipsychotics5 . The literature has emphasised male sexual problems with less data available on female or couple problems.

Recreational drugs such as alcohol, narcotics, stimulants and hallucinogens also affect sexual function. Short-term use of alcohol affects sexual desire by decreasing inhibitions, but also diminishes performance and delays orgasm and ejaculation. Many substance abusers report better sexual function, but often their partners report the opposite.6

Sexual function consists of the phases of sexual desire, arousal and orgasm. Both men and women can experience problems in any of these phases. Low desire, lack of swelling and lubrication in women, erectile dysfunction, premature, retrograde or absent ejaculation, anorgasmia and painful sex not only affect the individual, but also impact on their partner.

Talking to the patient

Whether patients report their sexual problems depends on several factors, including whether the patient is comfortable disclosing these problems, and whether the clinician is willing to ask about sexual issues and does so in a sensitive way.7 ,8Patients on long-term medications may not be aware that their sexual problems have developed as a result of their treatment. Conversely some may blame their drugs for sexual problems which are due to relationship difficulties or other stressors. Some doctors consider that asking patients if they had noticed any sexual adverse effects from their drugs may 'suggest' them to the patient, and possibly result in non-adherence. Patients attributing their sexual problems to their drugs are less likely to continue the treatment even when necessary for their health.9 The consultation should include discussion of the patient's sexual issues so these can be considered in treatment decisions.

Treatments for hypertension

Hypertension is associated with sexual dysfunction.10 Antihypertensives may also contribute to the problem and lead to low treatment adherence.4

Men

In an international survey, 20% of men using beta blockers (beta adrenoreceptor antagonists) for hypertension had erectile dysfunction.11 Centrally-acting alpha agonists (for example clonidine) and diuretics have also been implicated in impairing sexual function.4 The aldosterone receptor blocker spironolactone also blocks the androgen receptor and is associated with erectile dysfunction and gynaecomastia.

Women

Sexual dysfunction is more common in women with hypertension (before treatment) compared to normotensive women (42% vs 19%).12 Although the sexual effects of antihypertensives have been poorly studied in women, these drugs may have similar adverse effects on the arousal phase as in men, leading to failure of swelling and lubrication. Decreased sexual desire (41% of women) and sexual pleasure (34%) have been reported.13 Alpha adrenergic drugs such as clonidine and prazosin also reduce desire (in a small, randomised trial)14 and arousal15 . The angiotensin II receptor antagonist, valsartan, was associated with improved sexual desire and fantasies when compared with the beta blocker atenolol in women with hypertension.16

Psychoactive drugs

Aside from the medicine, it is important to be aware of the effects of psychiatric problems on the patient's relationship and address the psychosocial issues.17 Up to 70% of patients with depression have sexual dysfunction, which can affect any phase of sexual activity.18 Reports indicate that 30–80% of women and 45–80% of men with schizophrenia also experience sexual problems.19 In these patients, it may be difficult to distinguish the effects of the illness on sexual function from the effects of the drugs used for treatment.

Antidepressants

Many antidepressants cause sexual difficulties.17 ,20 Selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors inhibit desire, cause erectile dysfunction and decrease vaginal lubrication. They also impair orgasm in 5–71% of patients.18 ,21 ,22 This adverse effect is used therapeutically to delay premature ejaculation.

Tricyclic antidepressants inhibit sexual desire and orgasm.23,24 The effects of specific drugs vary depending on their mechanism of action. For example, clomipramine causes orgasmic difficulties in up to 90% of patients, while nortriptyline causes more erectile dysfunction but has less effect on orgasm.25

Monoamine oxidase inhibitors are also associated with sexual dysfunction. Although moclobemide was reported to increase sexual desire,24 the doses used in that study were considered subtherapeutic.

Other antidepressants such as venlafaxine and mirtazapine have variable negative effects on all aspects of sexual function. Initial reports on agomelatine in both male and female patients with major depressive disorder suggested significant antidepressant efficacy without significant sexual adverse effects. However, more recent reviews of the sexual effects are conflicting.26 ,27

Antipsychotics

Some antipsychotics may affect sexual function more than others (see Table 2).19 ,28 The only Cochrane review of antipsychotic-induced sexual dysfunction has reported a small number of studies relating to men, but none relating to women.29

Men taking antipsychotics report erectile dysfunction, decreased orgasmic quality with delayed, inhibited or retrograde ejaculation, and diminished interest in sex. Women experience decreased desire, difficulty achieving orgasm, changes in orgasmic quality and anorgasmia. Dyspareunia, secondary to oestrogen deficiency, can result in vaginal atrophy and dryness. Galactorrhea is experienced in both sexes.28

A recent observational study of schizophrenia found that in patients with diminished sexual desire, ziprasidone was preferred over olanzapine.30 The majority of antipsychotics cause sexual dysfunction by dopamine receptor blockade. This causes hyperprolactinaemia with subsequent suppression of the hypothalamic–pituitary–gonadal axis and hypogonadism in both sexes. This decreases sexual desire and impairs arousal and orgasm. It also causes secondary amenorrhoea and loss of ovarian function in women and low testosterone in men.31 ,32 Although poorly understood, other neurotransmitter pathways including histamine blockade, noradrenergic blockade and anticholinergic effects may also be affected by antipsychotics.

Before commencing dopamine receptor antagonists it is useful to establish a baseline prolactin, as subsequent elevation can then be attributed to the drug. Non-drug induced causes of hyperprolactinaemia such as pituitary tumours should be considered in patients on dopamine receptor antagonists.33

Antiepileptics

Sexual dysfunction is common in patients on antiepileptic drugs.34 Gabapentin and topiramate have been associated with orgasmic dysfunction in both men and women, and reduced libido in women.35-37

Contraceptives

Oral contraceptives decrease circulating free testosterone. It is postulated that this decreases desire in women, although there is little evidence to support this.38 As with other disorders, the impact of social context including the relationship, and fear of pregnancy and sexually transmitted diseases are confounding influences in clinical reports of the impact of oral contraceptives.

Depot medroxyprogesterone acetate, used as a contraceptive in women, can cause weight gain, depression, vaginal atrophy and dyspareunia with decreased libido in up to 15% of women.39-41

Treatments for cancer

The impact of malignancy and its treatment on both the individual and his or her partner can have a significant negative influence on their sexual relationship. Many of the cancer treatments can lead to sexual dysfunction. As common examples, long-acting gonadotrophin-releasing hormone agonists used for prostate and breast cancer result in hypogonadism, with subsequent reduction in sexual desire, erectile dysfunction in men42, vaginal atrophy and dyspareunia in women as well as orgasmic dysfunction.34

Drugs for lower urinary tract symptoms and benign prostatic hyperplasia

Men who present with symptomatic benign prostatic hyperplasia and lower urinary tract symptoms have an increased incidence of sexual dysfunction. Overall, 72.2% of men with lower urinary tract symptoms had erectile dysfunction compared with 37.7% in those without lower urinary tract symptoms.43 Although surgery and various therapies can improve lower urinary tract symptoms, some of these treatments also cause or exacerbate erectile dysfunction and ejaculatory dysfunction.43

Alpha blockers such as doxazosin, tamsulosin, terazosin and alfuzosin for benign prostatic hyperplasia are reported to be no worse than placebo in their effects on sexual function, although tamsulosin was associated with approximately 10% increase in ejaculatory dysfunction in treated men.44

Other drugs that cause sexual dysfunction

Antiandrogens such as cyproterone acetate, cimetidine, digoxin and spironolactone block the androgen receptor. This reduces sexual desire in both sexes,45 and affects arousal and orgasm.

Steroids such as prednisone used for many chronic inflammatory disorders result in low serum testosterone which reduces sexual desire and causes erectile dysfunction.46 Immunosuppressive drugs such as sirolimus and everolimus are widely used in kidney transplantation and can impair gonadal function and cause erectile dysfunction.47 Protease inhibitors for HIV have also been implicated in sexual dysfunction and cause erectile problems in over half of men taking them.48

Many other drugs including antihistamines, pseudoephedrine, opioids and recreational drugs may cause sexual dysfunction and should be considered when assessing the patient.

Strategies to manage sexual dysfunction

Non-drug approaches include therapy with a clinical psychologist who understands sexual dysfunction. A variety of strategies have been tried to reverse drug-induced sexual dysfunction, including drug switching, dose reduction and drug holidays. Taking a phosphodiesterase type 5 inhibitor in anticipation of intercourse has become the standard of care for men.49-51 It improves erections in about 70% of men with hypertension.52 However, phosphodiesterase type 5 inhibitors are contraindicated in men using nitrates and should be used with caution in those on alpha blockers, where postural hypotension can be a problem. In women, sildenafil has shown promise for reversing the inadequate lubrication and delayed orgasm induced by selective serotonin reuptake inhibitors.53

Changing to an alternative drug is recommended for men and women taking antihypertensives. Alpha blockers, ACE inhibitors and calcium channel blockers are not considered to cause erectile dysfunction,54 while several studies have suggested that angiotensin II receptor antagonists may even improve sexual function. Beta ₁ -selective beta blockers such as nebivolol may have potential advantages in these patients.55

In patients taking antipsychotics, establish the cause of the hyperprolactinaemia then consider dose reduction or switching to prolactin-sparing drugs. Relationship counselling and addressing patient-specific concerns can be useful.28

In women, oestrogen cream can alleviate local symptoms such as atrophic vaginitis and dyspareunia. If a woman complains of sexual dysfunction while on an injectable progestogen, another form of contraceptive can be considered.34

Suggested solutions to gabapentin-induced anorgasmia include dose reduction, timing of dose away from planned coitus until anorgasmia no longer occurs, substitution with a different medication, and co-administration of other medications.35,36

Conclusion

Understanding both the impact of a disorder and the effects of its treatment on both the patient and their partner are critical to providing good clinical care. It is important for the clinician to acknowledge and encourage discussion regarding sexual function, as well as enquire about the impact of drugs on sexual function. This will ensure patients and their partners understand their sexual difficulties and treatment options.

REFERENCES

1. Leiblum SR, Rosen RC, editors. Principles and Practice of Sex Therapy. 3rd ed. The Guilford Press; 2000.
2. Levine SB, editor. Handbook of Clinical Sexuality for Mental Health Professionals. New York: Brunner-Routledge; 2003.
3. Conaglen HM, Conaglen JVHow to treat male sexual dysfunction. N Z Dr 2010 June 30;29-34.
4. Düsing RSexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005;65:773-86.
5. Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, et alImpact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 2004;19:415-22.
6. Cummins T, Miller S. The effects of drug abuse on sexual functioning. In: Levine SB, editor. Handbook of clinical sexuality for mental health professionals. New York: Brunner-Routledge; 2003. p. 443-56.
7. Gott M, Hinchliff S, Galena EGeneral practitioner attitudes to discussing sexual health issues with older people. Soc Sci Med 2004;58:2093-103.
8. Moreira ED Jr, Brock G, Glasser DB, Nicolosi A, Laumann EO, Paik A, et al Help-seeking behaviour for sexual problems: the global study of sexual attitudes and behaviors. Int J Clin Pract 2005;59:6-16 .
9. Segraves R. Recognizing and reversing sexual side effects of medications. In: Levine SB, editor. Handbook of clinical sexuality for mental health professionals. New York: Brunner-Routledge; 2003. p. 377-91.
10. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003;139:161-8.
11. Shabsigh R, Perelman MA, Lockhart DC, Lue TF, Broderick GAHealth issues of men: prevalence and correlates of erectile dysfunction. J Urol 2005;174:662-7.
12. Doumas M, Tsakiris A, Douma S, Grigorakis A, Papadopoulos A, Hounta A, et alBeneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl 2006;8:177-82.
13. Hanon O, Mounier-Vehier C, Fauvel JP, Marquand A, Jaboureck O, Justin EP, et al[Sexual dysfunction in treated hypertensive patients. Results of a national survey]. Arch Mal Coeur Vaiss 2002;95:673-7. French.
14. Hodge RH, Harward MP, West MS, Krongaard-Demong L, Kowal-Neeley MB Sexual function of women taking antihypertensive agents: a comparative study. J Gen Intern Med 1991;6:290-4.
15. Meston CM, Gorzalka BB, Wright JMInhibition of subjective and physiological sexual arousal in women by clonidine. Psychosom Med 1997;59:399-407.
16. Fogari R, Preti P, Zoppi A, Corradi L, Pasotti C, Rinaldi A, et alEffect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens 2004;17:77-81.
17. Brill MAntidepressants and sexual dysfunction. Fertil Steril 2004;81 Suppl 2:35-40.
18. Werneke U, Northey S, Bhugra DAntidepressants and sexual dysfunction. Acta Psychiatr Scand 2006;114:384-97.
19. Baggaley MSexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008;23:201-9.
20. Baldwin DSSexual dysfunction associated with antidepressant drugs. Expert Opin Drug Saf 2004;3:457-70.
21. Bostwick JMA generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. Mayo Clin Proc 2010;85:538-50.
22. Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HMEstimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry 2006;67:204-10.
23. Montgomery SA, Baldwin DS, Riley AAntidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J Affect Disord 2002;69:119-40.
24. Philipp M, Kohnen R, Benkert OA comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction. Int Clin Psychopharmacol 1993;7:149-53.
25. Stahl SMBasic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59 Suppl 4:5-14.
26. Kennedy SH, Rizvi SJAgomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010;24:479-99.
27. Howland RHPublication bias and outcome reporting bias: agomelatine as a case example. J Psychosoc Nurs Ment Health Serv 2011;49:11-4.
28. Kelly DL, Conley RRSexuality and schizophrenia: a review. Schizophr Bull 2004;30:767-79.
29. Berner MM, Hagen M, Kriston LManagement of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev 2007;1:CD003546.
30. Lambert M, Haro JM, Novick D, Edgell ET, Kennedy L, Ratcliffe M, et al Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 2005;111:232-43.
31. Haddad PM, Wieck AAntipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291-314.
32. Knegtering H, van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28 Suppl 2:109-23.
33. Inder WJ, Castle DAntipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 2011;45:830-7.
34. Carey JCPharmacological effects on sexual function. Obstet Gynecol Clin North Am 2006;33:599-620.
35. Clark JD, Elliott JGabapentin-induced anorgasmia. Neurology 1999;53:2209.
36. Grant AC, Oh HGabapentin-induced anorgasmia in women. Am J Psychiatry 2002;159:1247.
37. Labbate LA, Rubey RNGabapentin-induced ejaculatory failure and anorgasmia. Am J Psychiatry 1999;156:972.
38. Bancroft J, Sherwin BB, Alexander GM, Davidson DW, Walker AOral contraceptives, androgens, and the sexuality of young women: II. The role of androgens. Arch Sex Behav 1991;20:121-35.
39. Matson SC, Henderson KA, Mcgrath GJPhysical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol 1997;10:18-23.
40. Fraser IS, Dennerstein GJDepo-Provera use in an Australian metropolitan practice. Med J Aust 1994;160:553-6.
41. Heber KRMedroxyprogesterone acetate as an injectable contraceptive. Aust Fam Physician 1988;17:199-201, 204.
42. Berterö CAltered sexual patterns after treatment for prostate cancer. Cancer Pract 2001;9:245-51.
43. Miner M, Rosenberg MT, Perelman MATreatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006;28:13-25.
44. Gur S, Kadowitz PJ, Hellstrom WJGuide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction: implications for sexual dysfunction. Drugs 2008;68:209-29.
45. Conaglen HM, Conaglen JVSexual desire in women presenting for antiandrogen therapy. J Sex Marital Ther 2003;29:255-67.
46. Macadams MR, White RH, Chipps BEReduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986;104:648-51.
47. Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing LGonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007;20:305-11.
48. Moreno-Perez O, Escoin C, Serna-Candel C, Pico A, Alfayate R, Merino E, et al Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors. AIDS 2010;24:255-64.
49. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 2003;289:56-64.
50. Labbate LAPsychotropics and sexual dysfunction: the evidence and treatments. Adv Psychosom Med 2008;29:107-30.
51. Taylor MJ, Rudkin L, Hawton KStrategies for managing antidepressant- induced sexual dysfunction: systematic review of randomised controlled trials. J Affect Disord 2005;88:241-54.
52. Kloner RErectile dysfunction and hypertension. Int J Impot Res 2007;19:296-302.
53. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008;300:395-404.
54. Bradley HA, Wiysonge CS, Volmink JA, Mayosi BM, Opie LHHow strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006;24:2131-41.
55. Cheng JWNebivolol: a third-generation beta-blocker for hypertension. Clin Ther 2009;31:447-62..